• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay Kits
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • MAPK8 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • MAPK8 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

How a Tyrosine Kinase Inhibitor Is Giving Hope to Lung Cancer Patients

by Bellbrook Labs / Tuesday, 20 August 2019 / Published in Emerging Targets
tyrosine kinase inhibitor lung cancer

According to the American Cancer Society, lung cancer is the leading cause of cancer death each year and accounts for approximately 13% of all new cases. The most common type being non-small cell lung cancer (NSCLC). Although smoking is the biggest contributor, other factors such as genetics and environmental pollutants contribute to lung cancer of all types. However, for those living with the disease, treatment is more of a concern and reasonably so. Like with other cancers, the choice of treatment whether surgical, radiation, chemotherapy or targeted drug therapy, depends on how far along the cancer is and the type.¹  Epidermal growth factor receptor (EGFR) a receptor tyrosine kinase, is of particular interest due to its role in cell growth and division. Mutations in EGFR and/or its cell signaling pathway result in several types of cancer including lung cancer.

Role of a Tyrosine Kinase Inhibitor in Targeted Drug Therapy

Researchers have found a few mutated genes in NSCLC patients; therefore targeting these genes for treatment is a priority. For example, patients with mutations in EGFR are more sensitive to EGFR inhibitor therapies.²  More specifically, mutations found in the tyrosine domain of EGFR can be targeted with an EGFR tyrosine kinase inhibitor such as gefitinib (a first-generation EGFR inhibitor).³ Compared to standard chemotherapy, gefitinib was found to be more effective in patients with advanced NSCLC harboring sensitive EGFR mutations.³

Over the years there have been improvements made that developed into second-generation EGFR tyrosine kinase inhibitor such as dacomitinib which has demonstrated both progression-free survival and overall survival when given as first-line therapy to NSCLC patients.4 Drug resistance to first-generation EGFR inhibitors made improvements necessary in some cases in order to keep cancer at bay.

A multitude of research and subsequent clinical trials are done to compare the various drug options. Other than determining how to better identify patients with a high chance of benefiting from EGFR inhibitors, some of the objectives of the research are as follows:

  • Effectiveness
  • Toxicity
  • Side effects
  • Ability to be multi-targeted

Although dacomitinib appears to be an important first-line agent in EGFR-mutated NSCLC, there are increased side effects of diarrhea, rash, stomatitis, and paronychia compared with first-generation EGFR inhibitors.4 However, if the patient can handle the side effects, the enhanced survival rate is worth it.


Learn how to determine drug-target residence times for EGFR inhibitors with this guide from BellBrook Labs.

A Guide to Measuring Drug-Target Residences Times with Biochemical Assays

Get the Guide


References

  1. About Non-Small Cell Lung Cancer. What Is Non-Small Cell Lung Cancer? :1-14. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html
  2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 2010;362(25):2380-2388. doi:10.1056/NEJMoa0909530
  3. Growth SE, Receptor F. Oncologist. 2007:325-330. doi:10.1634/theoncologist.12-3-325
  4. Lau, S.C.M., Batra, U., Mok, T.S.K. et al. Drugs (2019) 79: 823. https://doi.org/10.1007/s40265-019-01115-y
  5. Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244-2250. doi:10.1200/JCO.2018.78.7994
Tagged under: kinase assay, Transcreener ADP Kinase Assay, tyrosine kinase inhibitors

What you can read next

NSP14 - Coronavirus Target
NSP14 – A Promising SARS-CoV-2 Therapeutic Target
Autoimmune Disease News
NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer
New Target for Heart Disease and Cancer: Glucosylceramide Synthase (GCS)

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARG in Human Immunity

    Discovering the Emerging Importance of PARG in Immunity

    Poly (ADP-ribose) glycohydrolase (PARG), along ...
  • Helicases Used in Innate Immunity

    Helicases as Powerful Tools in Innate Immunity

    Helicases are among the largest and most highly...
  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP